You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study

 

Online download statistics by month:

Online download statistics by month: January 2022 to March 2024

AbstractFullPdf
Jan 2022402412144
Feb 202213213463
Mar 2022949538
Apr 2022767926
May 2022898939
Jun 202210410930
Jul 2022899021
Aug 202212712739
Sep 2022939439
Oct 202211311539
Nov 2022787831
Dec 2022787818
Jan 2023494916
Feb 2023656516
Mar 2023464739
Apr 2023363631
May 2023414118
Jun 2023232411
Jul 2023444422
Aug 202328298
Sep 2023414218
Oct 2023474733
Nov 2023353513
Dec 2023484921
Jan 2024313118
Feb 2024343426
Mar 2024303036
Total20732103853